Wella Tablet: Each coated tablet contains Amitriptyline 12.5 mg as Amitriptyline Hydrochloride BP and Chlordiazepoxide BP 5 mg.
Wella DS Tablet: Each coated tablet contains Amitriptyline 25 mg as Amitriptyline Hydrochloride BP and Chlordiazepoxide BP 10 mg.
Wella & Wella DS contain Amitriptyline and Chlordiazepoxide. Amitriptyline is a dibenzocycloheptadiene tricyclic antidepressant which increases synaptic concentration of serotonin and/or norepinephrine in the CNS by blocking the neuronal reuptake of norepinephrine and serotonin. Chlordiazepoxide is a benzodiazepine which enhances the activity of the inhibitory transmitter GABA in different parts of CNS by increasing neuronal membrane permeability to chloride ions resulting to hyperpolarisation and stabilisation. It has some muscle relaxant and anticonvulsant activity
Route of administration: Wella & Wella® DS should be taken in oral route. The recommended dose of Wella® is 3 or 4 tablets daily in divided doses which may be satisfactory in patients who do not tolerate higher doses. When a satisfactory response is obtained, dosage should be reduced to the smallest amount needed to maintain the remission. The larger portion of the total daily dose may be taken at bedtime. In some patients, a single dose at bedtime may be sufficient. In general, lower dosages are recommended for elderly patients. The recommended dose of Wella® DS is initially 3 or 4 tablets daily in divided doses which may be increased to 6 tablets daily as required. Some patients respond to smaller doses and can be maintained on 2 tablets daily.
MAO inhibitors provoke severe hyperpyretic crises and serotonin syndrome (contraindicated; 14-day washout); alcohol and CNS depressants potentiate sedation and respiratory depression; anticholinergics worsen antimuscarinic effects.
This combination is contraindicated in patients with known hypersensitivity to either benzodiazepines or tricyclic antidepressants or any components of this product. This drug is contraindicated during the acute recovery phase following myocardial infarction.
Common: Drowsiness, dry mouth, constipation, blurred vision, dizziness, bloating, anorexia, fatigue, weakness, restlessness, lethargy.
Overdose
Deaths may occur from overdosage with this class of drugs. Critical manifestations of overdose includes cardiac dysrhythmias, severe hypotension, convulsions and CNS depression, including coma; therefore, hospital monitoring is required as soon as possible.
Category D. Benzodiazepine and tricyclic combination; risk of congenital anomalies and neonatal withdrawal; avoid during pregnancy. Lactation: Excreted in breast milk; nursing should not be undertaken.
Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.